Founded in 2017, Jiangsu Medomics Medical Technology Co., Ltd, as an international high-tech enterprise, focuses on diagnosis of microorganisms, tumors and some rare diseases, mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and automatic instruments.
At the very beginning of COVID-19 on early 2020, Medomics developed IgM/IgG antibody detecting kit with the team of Zhong Nanshan. And Medomics published the first research paper on international journal together with State Key Laboratory of Respiratory Disease. The detecting kit was validated by CDC, Harvard Medical School and Columbia University Irving Medical Center etc. Until May 2020, the kit has been exported to dozens of countries and areas, making great help against SARS-Cov-2.
In 2021, Medomics’s series product of SARS-Cov-2 detection have been developed according to ISO 13485 Quality system and European CE Certification.